Evidence map›Paper›PMID 41432296›Full record

ArticleJournal of molecular cell biology2026

CD46 regulates hepatitis B virus entry by modulating cell-surface NTCP levels through cis-interaction.

Kei Miyakawa, Yusuke Nakai, Taichi Kameya, Hironori Nishitsuji, Koichi Watashi, Makoto Takeda, Tsukasa Seya, Kunitada Shimotohno, Yayoi Kimura, Akihide Ryo

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of molecular cell biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Kei MiyakawaAIDS Research Center, National Institute of Infectious Diseases, Japan Institute for Health Security, Tokyo 208-0011, Japan.
Yusuke NakaiInfluenza Research Center, National Institute of Infectious Diseases, Japan Institute for Health Security, Tokyo 208-0011, Japan.
Taichi KameyaDepartment of Bioinformatics and Integrative Omics, National Institute of Infectious Diseases, Japan Institute for Health Security, Tokyo 208-0011, Japan.
Hironori NishitsujiDepartment of Virology, Fujita Health University School of Medicine, Aichi 470-1192, Japan.
Koichi WatashiDepartment of Drug Development, National Institute of Infectious Diseases, Japan Institute for Health Security, Tokyo 208-0011, Japan.ORCID 0000-0002-4536-9966
Makoto TakedaDepartment of Microbiology, Graduate School of Medicine and Faculty of Medicine, The University of Tokyo, Tokyo 113-0033, Japan.
Tsukasa SeyaNebuta Research Institute for Life Sciences, Aomori University, Aomori 030-0943, Japan.
Kunitada ShimotohnoInstitute of Microbial Chemistry (BIKAKEN), Tokyo 141-0021, Japan.
Yayoi KimuraAdvanced Medical Research Center, Yokohama City University, Kanagawa 236-0004, Japan.
Akihide RyoDepartment of Microbiology, Yokohama City University School of Medicine, Kanagawa 236-0004, Japan.

Funding

Japan Agency for Medical Research and Development JP223fa627005Japan Agency for Medical Research and Development JP23fk0310507Japan Society for the Promotion of Science JP23K27419Japan Society for the Promotion of Science JP23K27641Takeda Science Foundation
6 · The paper itself

Abstract

Hepatitis B virus (HBV) infection remains a major global health challenge. While sodium taurocholate co-transporting polypeptide (NTCP) is the primary receptor for HBV entry, the molecular mechanisms regulating NTCP-mediated viral entry remain incompletely understood. Here, we identified CD46 as a crucial regulatory factor for NTCP membrane expression. We found that CD46 interacted with NTCP in cis at the plasma membrane through proximity-based labeling screening. The depletion of CD46 significantly reduced cell-surface NTCP levels and HBV infection in hepatocytes. Anti-CD46 monoclonal antibodies, particularly clone E4.3, inhibited HBV infection by triggering NTCP internalization from the plasma membrane to intracellular vesicles. The antiviral effect of CD46 antibodies was also confirmed in primary human hepatocytes. Our study reveals a previously unknown mechanism regulating NTCP-mediated HBV entry and suggests CD46 as a potential therapeutic target for HBV infection.

Indexed as

Hepatitis BHepatitis B virusMembrane Cofactor ProteinOrganic Anion Transporters, Sodium-DependentSymportersVirus InternalizationCell MembraneHepatocytesHep G2 CellsHumansProtein BindingCD46 protein, humanMembrane Cofactor ProteinOrganic Anion Transporters, Sodium-Dependentsodium-bile acid cotransporterSymportershepatitis B virus (HBV)proximity-based labelingsodium taurocholate co-transporting polypeptide (NTCP)viral entry

Identifiers

PMID41432296
PMCPMC13424813

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.